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Identity 
Other names: KIP1; P27KIP1 
Location: 12p13 
Local order:  centromere - CDNK1B - ETV6 - PRB - 
KCNA5 - CACNL1A1 - telomere. 
 
CDKN1B (12p3) - Courtesy Mariano Rocchi. 
DNA/RNA 
Description 
Coding region from two exons. 
Transcription 
2.5 Kb mRNA; CDKN1B gene regulation by 




198 amino-acids; 22 kDa; homology to WAF1, limited 
to a 60 amino acid segment in the N-term half of the 
protein (residues 28-88); putative bipartite nuclear 
localization signal near the C-term (153-169); C-term 
extension of 23 amino acids that contains a consensu  
Cdc2 phosphorylation site. 
Expression 
Expressed in all tissues tested; high levels in skeletal 




- CDKN1B is a negative regulator implicated in G1 
arrest mediated by TGFb, cell-cell contact, agents that
elevate cyclic AMP and rapamycin; CDKN1B binds to 
and acts as a stoichiometric inhibitor of G1-cyclin-
cyclin dependent kinase complexes (cyclin E-Cdk2, 
cyclin A-Cdk2, cyclin D-Cdk4 (restriction point)), 
controlling G1 to S phase transition or exit from the 
cell cycle; CDKN1B coordinates the varied inputs from 
the extracellular environment; post-translational 
ubiquitin-mediated proteasomal proteolysis represents 
the major regulatory influence of CDKN1B protein 
level. 
- in CDKN1B knockout mouse, CDKN1B defect 
causes multi-organ hyperplasia with features of 
gigantism, abnormalities of thymus, retina, pituitary, 
adrenal glands and gonadal organs (ovulatory defect 





Note: hemizygous interstitial deletion is found in 10% 
of cytogenetically normal ANLL; monoallelic deletion 
found in 5% ANLL cases, but not described in ALL; no 
case so far of CDKN1B mutations in leukemia 
samples. 
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Primary breast cancers 
Prognosis 
A low nuclear expression of CDKN1B protein is a 
significant predictor of poor disease-free survival; in 
contrary, high level of CDKN1B protein expression 
combined with low level expression of its target (cyclin 
E-Cdk2) correlates with about 90% 10-yr overall 
survival in the lymph node-negative subgroup. 
Primary colorectal carcinomas 
Prognosis 
CDKN1B is an independent prognostic marker: low 
levels are significantly correlated with a poor 
prognosis. 
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